Free Trial
NASDAQ:IRWD

Ironwood Pharmaceuticals Q2 2025 Earnings Report

Ironwood Pharmaceuticals logo
$0.90 +0.02 (+1.92%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$0.92 +0.02 (+2.02%)
As of 08/8/2025 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals EPS Results

Actual EPS
$0.14
Consensus EPS
-$0.02
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Ironwood Pharmaceuticals Revenue Results

Actual Revenue
$85.24 million
Expected Revenue
$62.02 million
Beat/Miss
Beat by +$23.22 million
YoY Revenue Growth
N/A

Ironwood Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Ironwood Pharmaceuticals' Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

Ironwood Pharmaceuticals Earnings Headlines

Ironwood (IRWD) Q2 EPS Jumps 600%
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD), a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

View Ironwood Pharmaceuticals Profile

More Earnings Resources from MarketBeat